Zacks Research Issues Pessimistic Outlook for ALLO Earnings

Key Points

• Analysts at Zacks Research have lowered their Q2 2025 earnings per share estimate for Allogene Therapeutics from ($0.27) to ($0.28), with a full-year earnings consensus estimate of ($1.28) per share.
• Several analysts have recently adjusted their ratings and price targets for Allogene, with estimates ranging from a buy rating and a price target of $10.00 by Royal Bank of Canada to a downgrade and a price target cut to $4.00 by Citigroup.
• The stock of Allogene Therapeutics is currently trading around $1.50, reflecting a market capitalization of approximately $328.10 million and a twelve-month trading range between $0.86 and $3.78.

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities research analysts at Zacks Research cut their Q2 2025 earnings per share estimates for shares of Allogene Therapeutics in a research note issued on Wednesday, July 23rd. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of ($0.28) for the quarter, down from their prior forecast of ($0.27). The consensus estimate for Allogene Therapeutics' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Allogene Therapeutics' Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.03) EPS, Q1 2026 earnings at ($0.29) EPS, Q2 2026 earnings at ($0.30) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS and FY2027 earnings at ($1.16) EPS.

Several other equities research analysts have also recently issued reports on the company. Truist Financial lowered their price objective on Allogene Therapeutics from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Citizens Jmp cut Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 14th. Oppenheimer lowered their target price on Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Royal Bank Of Canada restated an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Finally, Robert W. Baird lowered their target price on Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.44.

Allogene Therapeutics Price Performance

ALLO stock traded down $0.01 during trading on Monday, hitting $1.29. The stock had a trading volume of 1,068,786 shares, compared to its average volume of 4,193,696. Allogene Therapeutics has a twelve month low of $0.86 and a twelve month high of $3.78. The stock has a market capitalization of $281.07 million, a P/E ratio of -1.04 and a beta of 0.31. The company's 50-day moving average price is $1.28 and its two-hundred day moving average price is $1.53.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28).

Institutional Trading of Allogene Therapeutics

Institutional investors have recently made changes to their positions in the company. PAX Financial Group LLC purchased a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $27,000. RPO LLC purchased a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $31,000. Caption Management LLC purchased a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $32,000. Syon Capital LLC purchased a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $39,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Allogene Therapeutics in the first quarter valued at approximately $28,000. Hedge funds and other institutional investors own 83.63% of the company's stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).